Methyl-TMA-2, or N-methyl-TMA-2, also known as N-methyl-2,4,5-trimethoxyamphetamine, is a drug of the phenethylamine, amphetamine, and DOx families. It is the N-methyl derivative of 2,4,5-trimethoxyamphetamine (TMA-2) as well as the α,N-dimethyl derivative of 2C-O (2,4,5-trimethoxyphenethylamine).
Use and effects N-Methylation of psychedelic phenethylamines has invariably greatly reduced or eliminated their hallucinogenic activity. Examples of this include related compounds like Beatrice (N-methyl-DOM) and methyl-DOB (N-methyl-DOB), which at assessed doses appear to be inactive as psychedelics in humans. In accordance with the preceding findings, per Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), methyl-TMA-2 was inactive at doses of up to 120 mg orally. For comparison, the active dose range of TMA-2 is 20 to 40 mg orally.
History Methyl-TMA-2 was first described in the scientific literature by at least 1984. It was subsequently described further by Shulgin in PiHKAL in 1991.
Society and culture
Legal status
Canada Methyl-TMA-2 is a controlled substance in Canada under phenethylamine blanket-ban language.
See also DOx (psychedelics) Methyl-TMA Beatrice (N-methyl-DOM) N-Methyl-DOET N-Methyl-DOB Methyl-DMA (N-methyl-2,5-DMA) N-Methylmescaline Trichocereine (N,N-dimethylmescaline) 2,4,5-Trihydroxymethamphetamine (THMA)
References
External links METHYL-TMA-2 - Isomer Design


